Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QR-442
- Development stage
- Preclinical
- Lead developer
- Quigley Pharma
01
Overview
QR-442 is an investigational drug candidate originally developed by Quigley Pharma, Inc., a subsidiary of The Quigley Corporation (now ProPhase Labs). The drug was being explored for potential therapeutic applications in immune system diseases and nervous system disorders. While it was part of a pipeline of compounds investigated for anti-inflammatory and immunomodulatory properties, specific details regarding its active pharmaceutical ingredient, molecular target, and modality have not been publicly disclosed. Following corporate restructuring and a shift in the developer's business focus toward diagnostic services, active development of QR-442 appears to have stalled, and its current global research and development status is listed as pending or inactive.
Beyond the preview
Go deeper on QR-442.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QR-442.